Pharmacokinetic Study of the HCV Protease Inhibitor BocePRevir and the Proton Pump Inhibitor OMeprazOle (PROMO)

Trial Profile

Pharmacokinetic Study of the HCV Protease Inhibitor BocePRevir and the Proton Pump Inhibitor OMeprazOle (PROMO)

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Feb 2013

At a glance

  • Drugs Boceprevir (Primary) ; Omeprazole
  • Indications Dyspepsia; Gastro-oesophageal reflux; Helicobacter pylori infections; Hepatitis C; Peptic ulcer; Zollinger-Ellison syndrome
  • Focus Pharmacokinetics
  • Acronyms PROMO
  • Most Recent Events

    • 21 May 2012 Actual end date (January 2012) added as reported by ClinicalTrials.gov.
    • 21 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Nov 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top